Genzyme reports positive top-line results of tower,
a pivotal phase iii trial for aubagio (teriflunomide)
in relapsing multiple sclerosis
Sanofi and its subsidiary Genzyme announced top–line results from the TOWER (Teriflunomide Oral in people With relapsing remitting multiplE scleRosis) trial that assessed the efficacy and safety of once–daily, oral teriflunomide in patients with relapsing forms of multiple sclerosis (MS). In the study, patients receiving teriflunomide 14 mg had a statistically significant reduction in annualized relapse rate and risk of sustained accumulation of disability. Analysis of the full TOWER data is ongoing and results
will be presented at a forthcoming scientific meeting.
This double–blind, multi–center trial enrolled 1,169 patients
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.